Improving Blood Pressure and Cardiovascular Risk With Resistance Exercise in African Americans (BPVR)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03016351 |
Recruitment Status :
Recruiting
First Posted : January 10, 2017
Last Update Posted : November 2, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension Cardiovascular Diseases Vascular Diseases | Other: Aerobic Training Other: Resistance Training | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 140 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Improving Blood Pressure and Cardiovascular Risk With Resistance Exercise in African Americans |
Study Start Date : | October 2016 |
Estimated Primary Completion Date : | April 2023 |
Estimated Study Completion Date : | April 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Aerobic Training
Participants will undergo a supervised endurance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week. During each session, participants will complete a 5 min warm-up followed by 30-45 min of endurance exercise using cycle ergometry. Intensity will be monitored using heart rate monitors during each exercise session, and each participant will receive an exercise prescription with a heart range equivalent to 65-85% of their heart rate max. Participants will be asked to complete 30 min of exercise during each session in week 1, 35 min in week 2 and 40-45 min weeks 3-8 with a 5 min cool down period.
|
Other: Aerobic Training
After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration. |
Experimental: Resistance Training
Participants will undergo a supervised resistance training program in accordance with established guidelines. Each session will be monitored by a physical therapist or exercise physiologist. Sessions will be carried out 3 times per week, 45 min per session. Muscle strength will be determined once before and once after resistance training by measuring ten repetition maximum (10 RM) for each exercise. Eight exercises (three sets; 8-12 repetitions) will be used on each of the large muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). In addition, workloads will be progressively increased if the patients can lift the weight more than 12 repetitions.
|
Other: Resistance Training
After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration. |
- Changes in peripheral and central blood pressure [ Time Frame: Baseline (wk. 0), Pre-training (wk. 8), post- training (wk. 16), post detraining (wk. 24) ]
- Changes in arterial stiffness [ Time Frame: Baseline (wk. 0), Pre-training (wk. 8), post- training (wk. 16), post detraining (wk. 24) ]
- Changes in endothelial function [ Time Frame: Baseline (wk. 0), Pre-training (wk. 8), post- training (wk. 16), post detraining (wk. 24) ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Sedentary
- Body Mass Index of 18.5-40 kg/m²
- Born in the United States of either two African-American or two non-Hispanic Caucasian parents
- Blood pressure of at least 120/80 mmHg
Exclusion Criteria:
- Inability to give informed consent
- History of cardiovascular disease or cardiovascular events
- Hypertension (systolic >159 mmHg and diastolic >99 mmHg) or on more than one anti-hypertensive medication
- Diabetes Type I& II
- Hyperlipidemia, with an LDL-C >159 mg/dL and /or total-C >229 mg/dL
- Pregnancy (or intend to become pregnant while participating in study) or nursing
- Tobacco use in the past 6 months (including, but not limited to cigarettes, e-cigarettes, hookah, Nicorette, SNUs and chewing tobacco)
- Chronic inflammatory disease such as, but not limited to, cancer
- Chronic autoimmune diseases such as, but not limited to: lupus, multiple sclerosis, rheumatoid arthritis
- Adverse reaction to nitroglycerin
- Anemia with a hemoglobin < 8
- Head injury within last 6 months
- Seizure disorder
- Presence of renal disease with a creatinine > 1.5mg/dL
- Presence of liver disease with liver enzymes > 3x the upper limits of normal
- Currently abusing alcohol or illicit drugs
- Unreliability as a study subject, in the opinion of the Investigator
- Lidocaine allergy
- Amenorrhea
- Postmenopausal women

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03016351
Contact: Laurel Thur, MS | 312-355-0277 | lathur@uic.edu | |
Contact: Shane Phillips, PhD | 312-355-0277 | shanep@uic.edu |
United States, Illinois | |
University of Illinois at Chicago | Recruiting |
Chicago, Illinois, United States, 60612 | |
Contact: Laurel Thur, MS 312-355-0277 lathur@uic.edu | |
Contact: Shane Phillips, PhD 312-355-0277 shanep@uic.edu | |
Principal Investigator: Shane Phillips, PhD |
Principal Investigator: | Shane Phillips, PhD | University of Illinois at Chicago |
Responsible Party: | Shane Phillips, PT, PhD, Professor, University of Illinois at Chicago |
ClinicalTrials.gov Identifier: | NCT03016351 |
Other Study ID Numbers: |
2015-1091 R01HL130513-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | January 10, 2017 Key Record Dates |
Last Update Posted: | November 2, 2022 |
Last Verified: | October 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Hypertension Exercise African Americans Arterial Function Arterial Stiffness |
Hypertension Cardiovascular Diseases Vascular Diseases |